white → brown2 → black3
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
DiPT
N,N-Diisopropyltryptamine
DiPT is a psychedelic substance of the tryptamine class and a structural analog of DMT.1 First described in the scientific literature in 1959, its psychoactive properties in humans were characterized by Alexander Shulgin in the mid-1970s and detailed in his 1997 book TiHKAL. DiPT is distinctive among psychedelics for producing primarily auditory rather than visual effects, including perceived shifts in pitch and harmonic distortion. Individual sensitivity varies considerably, and it has been sold as a research chemical.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold~15 mg
Light15-25 mg
Moderate25-50 mg
Strong50-150 mg
Heavy150+ mg
Intensity of effects at a given dose varies widely between individuals; some users report overpowering effects at 50 mg while others report only mild effects at 100 mg. Start low to gauge individual sensitivity.
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
In a preliminary study of nine adult volunteers, orally administered DiPT produced a predominantly auditory syndrome. At active doses, participants commonly reported lethargy, a desire to lie down, emotional distance, little or no euphoria, and distortion of pitch and timbre. The study reported no visual-field distortion and no eyes-closed imagery.[cite:pmid-6949674]
Physical
At active oral doses in the preliminary study, lethargy and a desire to lie down were characteristic. Across the preliminary trials, two participants reported mild nausea, three reported muscular hyperreflexia, and slight pupil dilation occurred in most participants.[cite:pmid-6949674] Separate archival self-reports described ear pressure at 18 mg oral, poor handwriting at 25 mg oral, mild diarrhea five to ten hours after 100 mg oral, and tongue numbness after 8 mg smoked.[cite:url-erowid-org-tihkal04-shtml]
Uncomfortable
Cognitive
Participants in the preliminary study described distance from their surroundings or their own feelings, with little or no euphoria, and the experience was characterized as neutral rather than clearly pleasant or unpleasant.[cite:pmid-6949674] A later archival self-report at 250 mg oral described marked foreboding and an ominous, unreal quality; this high-dose report should not be generalized to usual doses.[cite:url-erowid-org-tihkal04-shtml]
Auditory
Auditory disturbance was the consistent finding of the preliminary study and, at the doses studied, essentially the entire sensory signature.[cite:pmid-6949674]
Tactile
See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)
Pharmacology
Pharmacodynamics
DiPT acts primarily as a full agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors, with 5-HT2A activation appearing to principally mediate its psychedelic effects in animal models. It also shows weak activity at the 5-HT1A receptor and functions as a weak serotonin reuptake inhibitor. Additional binding affinities have been reported at dopamine receptors, adrenergic receptors, and the dopamine and norepinephrine transporters, though the contribution of these interactions to its overall effects remains unclear. The mechanisms underlying DiPT's characteristic selective alterations of auditory perception are unknown.
Pharmacokinetics
DiPT has not received a formal human pharmacokinetic characterization. A preliminary study in nine volunteers reported oral effects beginning after 20–30 minutes and peaking after about 1.5–2 hours, but it did not measure blood or urine concentrations, bioavailability, clearance, or elimination half-life.citation needed The authors of that study proposed that the bulky N-isopropyl groups might resist N-dealkylation or oxidative deamination, but explicitly framed this as a hypothesis requiring kinetic and metabolic studies.1 A 2022 Drug Enforcement Administration review likewise stated that metabolism studies had not been conducted for DiPT.6
Interactions
Interactions not written up yet
An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Full Tolerance
Tolerance to the effects of DiPT develops almost immediately following ingestion.
Baseline Reset
Approximately 7 days without further consumption
Half Tolerance
Approximately 3 days
Cross Tolerance
Serotonergic psychedelics
Harm Potential
Addiction & Dependence
Psychological
Extremely LowDiPT is not habit-forming and the desire to use it can actually decrease with use. It is described as most often self-regulating.
Physical
No information exists regarding physical dependence or withdrawal symptoms. Unusually among psychedelics, DiPT did not show evidence of behavioral tolerance in rodent studies.7
Toxicity
Auditory System
DiPT is known to chronically alter the perception of sound and speech in some users, which may persist beyond the acute effects; ear pressure ranging from mild to painful has been reported, particularly when combined with MDMA.
Psychosis Risk
At typical doses, DiPT is described as producing lucid and clear-headed cognitive effects compared to other tryptamines. At very high doses (250mg), one report described delusional spiritual experiences including feeling spoken to by spirits and perceiving an 'anti-universe.'citation needed Confusion has been noted at higher doses.
Seizure Risk
DiPT produces convulsions at high doses in rodent studies.9 No human seizure cases are documented in the available literature.
History & Culture
Discovery and Development
DiPT was first characterized in the scientific literature by R.B. Barlow and colleagues in 1959.10 Alexander Shulgin began investigating the compound's effects in humans during the mid-1970s, with his initial findings dating to 1974 and basic properties…
Trip Reports
Loading related reports
Preparing section content
Still loading. Refresh if this section does not appear.
Legality
By Country
Illegal14
BelgiumIllegal (analog/blanket ban)DiPT is controlled in Belgium as a tryptamine derivative under Annexe IVa to the Royal Decree of 6 September 2017 regulating narcotic, psychotropic and soporific substances. The annex’s generic definition covers 2-(1H-indol-3-yl)ethanamine derivatives with each of the two amine substituents being CnH2n+1 (n=1–5), which includes DiPT’s two isopropyl substituents; manufacture, possession, supply, import and export are regulated under the decree’s authorization regime.
DenmarkIllegal (analog/blanket ban)Bekendtgørelse om euforiserende stoffer (bekendtgørelse nr. 405 af 26. marts 2026)14
DiPT is controlled in Denmark as a psychoactive simple derivative of DPT, which is included in List B of the Executive Order on Euphoric Substances. List B substances may be used only for medical or scientific purposes, and their import, export, sale, receipt, manufacture, processing, and possession are permitted only under the order's authorization rules. The order entered into force on 29 March 2026.
GermanyIllegalNeue-psychoaktive-Stoffe-Gesetz16
Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) as of July 18, 2019.17 Production, import with intent to distribute, administration to others, and trading are punishable offenses. Possession is prohibited but not subject to criminal penalties.
IrelandIllegal (analog/blanket ban)DiPT is controlled in Ireland under Schedule 1 of the Misuse of Drugs Regulations 2017 because it is structurally derived from tryptamine and has alkyl substitution at the side-chain nitrogen. The Regulations prohibit its production, supply, importation and exportation; possession without a statutory or regulatory authority is an offence under the Misuse of Drugs Act 1977. The Regulations have applied since 4 May 2017.
IsraelIllegal (analog/blanket ban)Dangerous Drugs Ordinance [New Version], 5733–197322
DiPT is a structural derivative of N,N-dimethyltryptamine, which is listed in Part A, Section B of the First Schedule to the Dangerous Drugs Ordinance [New Version], 5733–1973. It is therefore a dangerous drug: its possession, use, manufacture, import, export, supply, and trade are prohibited except as permitted by the Ordinance, regulations, or a licence from the Director-General.
NorwayIllegalForskrift om narkotika29
N,N-diisopropyltryptamine (DiPT) is listed in Norway's narcotics list in the Regulation on Narcotics. The regulation treats the listed substance as a narcotic drug subject to Norway's narcotics controls.
PolandIllegal (analog/blanket ban)Regulation of the Minister of Health of 17 August 2018 on the list of psychotropic substances, narcotic drugs and new psychoactive substances (consolidated text, Dz.U. 2024 poz. 1139)3031
DiPT (N,N-diisopropyltryptamine) is covered as a tryptamine derivative in group VI-NPS of the Regulation of the Minister of Health of 17 August 2018 on the list of psychotropic substances, narcotic drugs and new psychoactive substances. The group definition covers indole-3-alkylamines with alkyl substituents of up to six carbons at both amine positions, which encompasses DiPT's two isopropyl substituents. The regulation has been in force since 21 August 2018; under the Act on Counteracting Drug Addiction, unlawful possession of a new psychoactive substance is punishable by a fine, while unlawful manufacture and placing it on the market carry criminal penalties.
PortugalIllegalPortaria n.º 154/201332
Diisopropiltriptamina (DIPT) is listed in the annex to Portaria n.º 154/2013 as a new psychoactive substance. The listing prohibits the production, import, export, advertising, distribution, sale, possession and availability of the substance.
SingaporeIllegalN,N-Diisopropyltryptamine (DiPT) is expressly named at paragraph 19(10) of the current First Schedule’s Class A drugs. Paragraph 19 also controls the defined tryptamine structural group, including its ethers, salts, stereoisomers, and preparations or products; DiPT is therefore controlled as the named substance itself, not merely as an inferred analogue. The Act defines First Schedule substances as controlled drugs and, except as authorised, makes their import or export an offence; CNB records that the tryptamine group was moved to Class A on 1 May 2016.
South KoreaIllegalEnforcement Decree of the Narcotics Control Act37
Diisopropyltryptamine (DiPT) is listed as a psychotropic drug in Appendix 4 to the Enforcement Decree of the Narcotics Control Act. It is consequently controlled under the Narcotics Control Act.
SwedenIllegalSFS 2026:1109, amendment to the ordinance on control of narcotics38
The 2026 official amendment supersedes the 2019 proposed scheduling.
Controlled / restricted3
FinlandRestrictedValtioneuvoston asetus 1130/201415
Di-isopropyylitryptamiini (DIPT) is listed as a psychoactive substance prohibited from the consumer market in the annex to Government Decree 1130/2014. Its placing on the consumer market is prohibited under Finland's consumer-market psychoactive-substances regime.
New ZealandClass CClassified as a Class C controlled substance due to its structural relationship to DMT, which is covered under analogue provisions in New Zealand drug law.28
SwitzerlandRestrictedBetäubungsmittelverzeichnisverordnung (BetmVV-EDI), standing 13 March 202639
DiPT is covered generically by the current schedules rather than being expressly named; its status under the 2019 proposal is obsolete.
Not scheduled3
United StatesNot scheduledFederally unscheduled,44 though it may be considered an analogue of DET or 5-MeO-DiPT under the Controlled Substances Act. Sales for human consumption or possession with intent to ingest could potentially be prosecuted under the Federal Analogue Act.45 Specifically listed as Schedule I in Florida and Louisiana (since June 2013).
By state
Across the 50 states, the District of Columbia, and the permanent territories, most jurisdictions treat DiPT consistently with federal control; listed entries record independently verified differences in classification or coverage.
ArizonaIllegalAriz. Rev. Stat. § 13-3401(6)(a)(xxx)46
Arizona classifies DiPT as a dangerous drug through its N-methyltryptamine mimetic-substances definition. The statute expressly names DiPT, producing state control without relying on the federal analogue case-specific showing.
District of ColumbiaNot scheduledDiPT is not listed in the District's Schedule I. The District's published controlled-substances chapter defines controlled substances by the enumerated schedules and does not provide a controlled-substance-analog definition or automatic analogue rule for DiPT. Possession and distribution prohibitions therefore do not create the federal analogue-law outcome for unscheduled DiPT.
IdahoNot scheduledIdaho's Schedule I hallucinogen list includes DMT, DET, and 5-MeO-DiPT, but does not list DiPT. The reviewed Idaho controlled-substances chapter defines controlled substances by its schedules and contains no general controlled-substance-analogue provision applicable to DiPT.
MaineNot scheduledMaine does not list N,N-diisopropyltryptamine (DiPT) in its scheduled-drug schedules. The Schedule X tryptamine list instead names DET, DMT, DPT and AET, among other specifically listed substances; Maine's statutory definition makes a scheduled drug one named or described in section 1102.
New YorkNot scheduledNew York defines a controlled substance as a substance listed in one of the five schedules in Public Health Law § 3306. The current Schedule I(d) list names diethyltryptamine (DET) and the distinct 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), but does not list N,N-diisopropyltryptamine (DiPT); the reviewed state schedule supplies no general substituted-tryptamine class that reaches DiPT. New York's synthetic-drug prohibition reviewed here is limited to enumerated synthetic phenethylamines and synthetic cannabinoids, not tryptamines. This finding concerns New York state scheduling only and does not resolve any independently applicable federal analogue-law question.
North CarolinaIllegalN.C. Gen. Stat. § 90-89(3)(nn)57
North Carolina classifies substituted tryptamines as Schedule I controlled substances. The class covers a compound structurally derived from tryptamine by mono- or di-substitution of the amine nitrogen with alkyl or alkenyl groups. DiPT falls within that class, so State control is direct Schedule I control rather than only a federal-analogue contingency.
OregonNot scheduledOr. Rev. Stat. §§ 475.005(6), 475.03558
Oregon defines a controlled substance as a drug or immediate precursor classified in Schedules I through V under the federal Controlled Substances Act, as modified by the State Board of Pharmacy. DiPT is federally unscheduled, and Oregon’s definition does not create a general controlled-substance-analogue category. The reviewed State statutory framework therefore does not schedule DiPT or make it a controlled substance through an analogue provision.
IndiaNot scheduledDiPT (N,N-diisopropyltryptamine) is not listed in the Schedule to the Narcotic Drugs and Psychotropic Substances Act, 1985. The Act limits its definition of a psychotropic substance to a substance or material included in that Schedule; it does not create a general analogue category that extends the Schedule to unlisted substances.
NetherlandsNot scheduledOpiumwet27
DiPT (N,N-diisopropyltryptamine) is not listed in List I or List II of the Dutch Opium Act. It also does not fall within List IA, whose blanket controls cover only derivatives of 2-phenethylamine, synthetic cannabinoids, and derivatives of 4-aminopiperidine. The Act's prohibitions on import, export, preparation, sale, supply, transport, possession, and manufacture therefore do not apply to DiPT under those schedules.
References
Source Pages
Citations
- A T Shulgin, & M F Carter. (1980). N, N-Diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity. Communications in Psychopharmacology, 4(5), 363–369. https://bibliography.maps.org/resources/download/88441234567891011121314151617
- dose.wiki generation draft: dipt__dosage_duration.yaml, 24 July 2026, lines 53-104. github.com (n.d.). https://github.com/josikinzz/dosewiki-admin/blob/main/runs/gap-generation-2026-07-24/drafts/wave-02/dipt__dosage_duration.yaml#L53-L10412
- dose.wiki earlier article export: DiPT, 2 August 2026, lines 43-59. github.com (n.d.). https://github.com/josikinzz/dosewiki-admin/blob/main/runs/article-review-2026-08-02/articles/dipt.md#L43-L5912
- PsychonautWiki. psychonautwiki.org (n.d.). https://psychonautwiki.org/wiki/DiPT12
- DiPT structured drug record. tripbot.tripsit.me (n.d.). https://tripbot.tripsit.me/api/tripsit/getDrug/dipt12
- Drug Enforcement Administration. federalregister.gov (n.d.). https://www.federalregister.gov/documents/full_text/text/2022/01/14/2022-00713.txt12
- Douglas A. Smith, Jessica M. Bailey, Diarria Williams, & William E. Fantegrossi. (December 2014). Tolerance and cross-tolerance to head twitch behavior elicited by phenethylamine- and tryptamine-derived hallucinogens in mice. J Pharmacol Exp Ther, 351(3), 485–491. https://doi.org/10.1124/jpet.114.2193371
- Simon L. Hill, & Simon H. L. Thomas. (October 2011). Clinical toxicology of newer recreational drugs. Clinical Toxicology, 49(8), 705–719. https://doi.org/10.3109/15563650.2011.6153181
- Michael B. Gatch, Michael J. Forster, Aaron Janowsky, & Amy J. Eshleman. (July 2011). Abuse liability profile of three substituted tryptamines. The Journal of Pharmacology and Experimental Therapeutics, 338(1), 280–289. https://doi.org/10.1124/jpet.111.1797051
- R. B. BARLOW, & I. KHAN. (March 1959). Actions of some analogues of tryptamine on the isolated rat uterus and on the isolated rat fundus strip preparations. British Journal of Pharmacology and Chemotherapy, 14(1), 99–107. https://doi.org/10.1111/j.1476-5381.1959.tb00934.x1
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes8 human edits · latest
Times are UTCNewest first
31 July 2026
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the DiPT article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.
